BACKGROUND AND OBJECTIVES: Within the last few years, anti-human leukocyte antigen detection assays have significantly improved. This study asked, using the Luminex single-antigen assay, whether an allograft nephrectomy allowed donor-specific alloantibodies to appear that were not previously detected in the serum when the failed kidney was still in place. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: After losing the kidney allograft and stopping immunosuppressive therapy, the proportions of donor-specific alloantibodies and nondonor-specific alloantibodies were compared in patients who had (n=48; group I) and had not (n=21; group II) undergone an allograft nephrectomy. Allograft nephrectomies were performed at 150 days after kidney allograft loss, and the time between allograft nephrectomy and last follow-up was 538 ± 347 days. RESULTS: At kidney allograft loss, donor-specific alloantibodies were detected in three group II patients (14.2%) and six group I patients (12.5%). At last follow-up, donor-specific alloantibodies were detected in 11 patients (52.4%) without and 39 patients (81%) with an allograft nephrectomy (P=0.02). Anti-human leukocyte antigen class I donor-specific alloantibodies were positive in 23.8% of group II and 77% of group I patients (P<0.001); anti-human leukocyte antigen class II donor-specific alloantibodies were positive in 42.8% of group II and 62.5% of group I patients. Independent predictive factors for developing donor-specific alloantibodies after losing kidney allograft and stopping immunosuppressants were number of anti-human leukocyte antigen A/B mismatches at transplantation (zero versus one or more) and allograft nephrectomy. CONCLUSIONS: The development of donor-specific alloantibodies was significantly greater in patients with a failed kidney who had undergone an allograft nephrectomy compared with those patients who had not undergone allograft nephrectomy.
BACKGROUND AND OBJECTIVES: Within the last few years, anti-human leukocyte antigen detection assays have significantly improved. This study asked, using the Luminex single-antigen assay, whether an allograft nephrectomy allowed donor-specific alloantibodies to appear that were not previously detected in the serum when the failed kidney was still in place. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: After losing the kidney allograft and stopping immunosuppressive therapy, the proportions of donor-specific alloantibodies and nondonor-specific alloantibodies were compared in patients who had (n=48; group I) and had not (n=21; group II) undergone an allograft nephrectomy. Allograft nephrectomies were performed at 150 days after kidney allograft loss, and the time between allograft nephrectomy and last follow-up was 538 ± 347 days. RESULTS: At kidney allograft loss, donor-specific alloantibodies were detected in three group II patients (14.2%) and six group I patients (12.5%). At last follow-up, donor-specific alloantibodies were detected in 11 patients (52.4%) without and 39 patients (81%) with an allograft nephrectomy (P=0.02). Anti-human leukocyte antigen class I donor-specific alloantibodies were positive in 23.8% of group II and 77% of group I patients (P<0.001); anti-human leukocyte antigen class II donor-specific alloantibodies were positive in 42.8% of group II and 62.5% of group I patients. Independent predictive factors for developing donor-specific alloantibodies after losing kidney allograft and stopping immunosuppressants were number of anti-human leukocyte antigen A/B mismatches at transplantation (zero versus one or more) and allograft nephrectomy. CONCLUSIONS: The development of donor-specific alloantibodies was significantly greater in patients with a failed kidney who had undergone an allograft nephrectomy compared with those patients who had not undergone allograft nephrectomy.
Authors: A K Khakhar; V B Shahinian; A A House; N Muirhead; D J Hollomby; S H Leckie; V C McAlister; J L Chin; A M Jevnikar; P P W Luke Journal: Transplant Proc Date: 2003-03 Impact factor: 1.066
Authors: S G Tullius; M Nieminen; W O Bechstein; S Jonas; T Steinmüller; J Pratschke; K Zeilinger; E Graser; H D Volk; P Neuhaus Journal: Transplant Proc Date: 1997-11 Impact factor: 1.066
Authors: S G Tullius; M Nieminen; W O Bechstein; S Jonas; T Steinmüller; J Pratschke; K Zeilinger; E Graser; H D Volk; P Neuhaus Journal: Transplantation Date: 1997-07-15 Impact factor: 4.939
Authors: Juan M López-Gómez; Isabel Pérez-Flores; Rosa Jofré; Diana Carretero; Patrocinio Rodríguez-Benitez; Maite Villaverde; Rafael Pérez-García; George M Nassar; Enrique Niembro; Juan Carlos Ayus Journal: J Am Soc Nephrol Date: 2004-09 Impact factor: 10.121
Authors: Eduardo Mazzucchi; Wiliam C Nahas; Ioannis M Antonopoulos; Afonso C Piovesan; Luis E Ianhez; Sami Arap Journal: J Urol Date: 2003-09 Impact factor: 7.450
Authors: Samer M T Al-Geizawi; Rajinder P Singh; Jack M Zuckerman; Jay A Requarth; Alan C Farney; Jeffrey Rogers; Jacob Taussig; Giuseppe Orlando; Robert J Stratta Journal: J Nephrol Date: 2014-09-30 Impact factor: 3.902
Authors: Greg Knoll; Patricia Campbell; Michaël Chassé; Dean Fergusson; Tim Ramsay; Priscilla Karnabi; Jeffrey Perl; Andrew A House; Joseph Kim; Olwyn Johnston; Rahul Mainra; Isabelle Houde; Dana Baran; Darin J Treleaven; Lynne Senecal; Lee Anne Tibbles; Marie-Josée Hébert; Christine White; Martin Karpinski; John S Gill Journal: J Am Soc Nephrol Date: 2022-03-23 Impact factor: 14.978